查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1140055

抗核抗體檢測市場：按產品、按技術、按應用、按最終用途：2021-2031 年全球機會分析和行業預測

Antinuclear Antibody Test Market By Product, By Technique, By Application, By End-use : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 329 Pages | 商品交期: 2-3個工作天內

價格

全球抗核抗體檢測市場預計將從 2021 年的 12.949 億美元增長到 2030 年的 49.994 億美元，2022 年至 2031 年的複合年增長率為 14.97%。

抗核抗體 (ANA) 測試是一項血液測試，用於檢查表現出自身免疫性疾病症狀的患者是否存在自身抗體。自身抗體通常是針對體內細胞產生的，並且存在於血清中。

抗核抗體檢測的市場擴張受到政府健康保險、不斷增加的自身免疫性疾病宣傳活動和報銷規定的推動。例如，世界狼瘡聯合會 (WLF) 是一個由來自六大洲 75 個國家的大約 250 個狼瘡組織組成的聯盟，致力於幫助狼瘡患者。 WLF 提高公眾對狼瘡的認識，為狼瘡患者提供更好的醫療設施，並支持為患者提供抗核抗體檢測。

負責 ANA 測試的人員需要同時了解技術和疾病。如果您不了解兩者，您將無法完成檢查。全球市場最大的預計障礙可能是缺乏熟練的員工來操作測試套件。此外，高昂的測試成本使每個人都無法接受測試，預計這將阻礙市場在預測期內的增長。

抗核抗體檢測已從 COVID-19 大流行中受益，預計在大流行階段會出現顯著增長。抗核抗體檢測越來越受歡迎，這是這一市場增長的主要原因。這些測試表明人體內存在自身免疫性疾病，其檢測極為重要。此外，由於 COVID 陽性患者自身免疫性疾病的患病率上升，該市場正在開發中。所有這些因素都在支持 COVID-19 流行期間的市場擴張。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概覽

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特五力分析
  • 主要公司的定位
  • 市場動態
    • 驅動程序
    • 約束因素
    • 機會
  • COVID-19 影響分析
  • 監管準則
  • 價值鏈分析
  • 市場份額分析
  • 關鍵法規分析
  • 專利情況

第 4 章抗核抗體檢測市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 試劑和檢測試劑盒
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 系統
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 軟件和服務
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章抗核抗體檢測市場：按技術分類

  • 概覽
    • 市場規模和預測
  • ELISA
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 免疫熒光檢測
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 多重檢測
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章抗核抗體檢測市場：按應用劃分

  • 概覽
    • 市場規模和預測
  • 類風濕性關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 系統性紅斑狼瘡
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 乾燥綜合徵
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 硬皮病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章抗核抗體檢測市場：按最終用途分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 臨床實驗室
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 醫生辦公室實驗室
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 8 章抗糖尿病檢測市場：按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品分類
    • 北美市場規模和預測：按技術分類
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按產品分類
    • 歐洲市場規模和預測：按技術分類
    • 歐洲市場規模和預測：按應用
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 意大利
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按產品分類
    • 亞太市場規模和預測：按技術分類
    • 亞太地區的市場規模和預測：按應用
    • 亞太市場規模和預測：按最終用途分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳大利亞
      • 其他亞太地區
  • LAMEA
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按產品分類
    • LAMEA 市場規模和預測：按技術
    • LAMEA 市場規模和預測：按應用
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 阿聯酋
      • 南非
      • LAMEA 的其餘部分

第 9 章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 競賽儀表板
  • 比賽熱圖
  • 主要發展

第 10 章公司簡介

  • erba diagnostics mannheim gmbh
  • Bio-Rad Laboratories, Inc.
  • Trinity Biotech Plc.
  • Thermo Fisher Scientific, Inc.
  • Antibodies Incorporated
  • euroimmun medizinische labordiagnostika ag
  • Immuno Concepts NA Ltd.
  • Inova Diagnostics, Inc.
  • ZEUS Scientific, Inc.
Product Code: A03912

The global antinuclear antibody test market is envisioned to garner $ 4,999.4million by 2030, growing from $ 1,294.9 million in 2021 at a CAGR of 14.97% from 2022 to 2031.

An anti-nuclear antibody (ANA) test is a blood test performed to find out whether there are any autoantibodies present in the patient showing symptoms of autoimmune diseases. Autoantibodies are usually made by the body against its own cells, present in the serum.

The market expansion of anti-nuclear antibody testing is driven by government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, the World Lupus Federation (WLF) is an alliance of about 250 lupus organizations from 75 nations across six continents with the goal of helping lupus patients. WLF promotes lupus awareness among the general public and gives lupus patients access to improved medical care facilities like providing assistance in conducting antinuclear antibody tests of the patients.

The individual in charge of doing ANA tests needs to be knowledgeable about both technology and the condition. A person cannot complete the test without comprehending both. The greatest barrier for the global market in the anticipated term is expected to be a lack of skilled staff to operate the testing kits. Additionally, everyone cannot afford the test because of its high cost, which is expected to impede the market's growth throughout the projected time.

Antinuclear antibody testing is anticipated to benefit from the COVID-19 pandemic and experience substantial growth during the pandemic stage. Antinuclear antibody testing has become increasingly popular, which is the main cause of this market growth. These tests demonstrate the existence of autoimmune illnesses in a person's body, making their detection vital. Additionally, the market is developing due to the rising prevalence of autoimmune illnesses in the COVID positive patients. All of these factors support market expansion during the COVID-19 epidemic.

The key players profiled in this report include: Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antinuclear antibody test market analysis from 2021 to 2031 to identify the prevailing antinuclear antibody test market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antinuclear antibody test market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antinuclear antibody test market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Reagents Assay Kits
  • Systems
  • Software Services

By Technique

  • ELISA
  • Immunofluorescence Assay
  • Multiplex Assay

By Application

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjogren's Syndrome
  • Scleroderma
  • Others

By End-use

  • Hospitals
  • Clinical Laboratories
  • Physician Office Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • erba diagnostics mannheim gmbh
    • Bio-Rad Laboratories, Inc.
    • Trinity Biotech Plc.
    • Thermo Fisher Scientific, Inc.
    • Antibodies Incorporated
    • euroimmun medizinische labordiagnostika ag
    • Immuno Concepts NA Ltd.
    • Inova Diagnostics, Inc.
    • ZEUS Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Regulatory Guidelines
  • 3.8.Value Chain Analysis
  • 3.9.Market Share Analysis
  • 3.10.Key Regulation Analysis
  • 3.11.Patent Landscape

CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Reagents & Assay Kits
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Systems
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Software & Services
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 ELISA
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Immunofluorescence Assay
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Multiplex Assay
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Rheumatoid Arthritis
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Systemic Lupus Erythematosus
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Sjogren's Syndrome
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Scleroderma
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country
  • 6.6 Others
    • 6.6.1 Key market trends, growth factors and opportunities
    • 6.6.2 Market size and forecast, by region
    • 6.6.3 Market analysis by country

CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Hospitals
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Clinical Laboratories
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Physician Office Laboratories
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country
  • 7.5 Others
    • 7.5.1 Key market trends, growth factors and opportunities
    • 7.5.2 Market size and forecast, by region
    • 7.5.3 Market analysis by country

CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Product
    • 8.2.3 North America Market size and forecast, by Technique
    • 8.2.4 North America Market size and forecast, by Application
    • 8.2.5 North America Market size and forecast, by End-use
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Product
      • 8.2.6.1.2 Market size and forecast, by Technique
      • 8.2.6.1.3 Market size and forecast, by Application
      • 8.2.6.1.4 Market size and forecast, by End-use
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Product
      • 8.2.6.2.2 Market size and forecast, by Technique
      • 8.2.6.2.3 Market size and forecast, by Application
      • 8.2.6.2.4 Market size and forecast, by End-use
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Product
      • 8.2.6.3.2 Market size and forecast, by Technique
      • 8.2.6.3.3 Market size and forecast, by Application
      • 8.2.6.3.4 Market size and forecast, by End-use
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Product
    • 8.3.3 Europe Market size and forecast, by Technique
    • 8.3.4 Europe Market size and forecast, by Application
    • 8.3.5 Europe Market size and forecast, by End-use
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Product
      • 8.3.6.1.2 Market size and forecast, by Technique
      • 8.3.6.1.3 Market size and forecast, by Application
      • 8.3.6.1.4 Market size and forecast, by End-use
      • 8.3.6.2 United Kingdom
      • 8.3.6.2.1 Market size and forecast, by Product
      • 8.3.6.2.2 Market size and forecast, by Technique
      • 8.3.6.2.3 Market size and forecast, by Application
      • 8.3.6.2.4 Market size and forecast, by End-use
      • 8.3.6.3 France
      • 8.3.6.3.1 Market size and forecast, by Product
      • 8.3.6.3.2 Market size and forecast, by Technique
      • 8.3.6.3.3 Market size and forecast, by Application
      • 8.3.6.3.4 Market size and forecast, by End-use
      • 8.3.6.4 Spain
      • 8.3.6.4.1 Market size and forecast, by Product
      • 8.3.6.4.2 Market size and forecast, by Technique
      • 8.3.6.4.3 Market size and forecast, by Application
      • 8.3.6.4.4 Market size and forecast, by End-use
      • 8.3.6.5 Italy
      • 8.3.6.5.1 Market size and forecast, by Product
      • 8.3.6.5.2 Market size and forecast, by Technique
      • 8.3.6.5.3 Market size and forecast, by Application
      • 8.3.6.5.4 Market size and forecast, by End-use
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Product
      • 8.3.6.6.2 Market size and forecast, by Technique
      • 8.3.6.6.3 Market size and forecast, by Application
      • 8.3.6.6.4 Market size and forecast, by End-use
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Product
    • 8.4.3 Asia-Pacific Market size and forecast, by Technique
    • 8.4.4 Asia-Pacific Market size and forecast, by Application
    • 8.4.5 Asia-Pacific Market size and forecast, by End-use
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 China
      • 8.4.6.1.1 Market size and forecast, by Product
      • 8.4.6.1.2 Market size and forecast, by Technique
      • 8.4.6.1.3 Market size and forecast, by Application
      • 8.4.6.1.4 Market size and forecast, by End-use
      • 8.4.6.2 Japan
      • 8.4.6.2.1 Market size and forecast, by Product
      • 8.4.6.2.2 Market size and forecast, by Technique
      • 8.4.6.2.3 Market size and forecast, by Application
      • 8.4.6.2.4 Market size and forecast, by End-use
      • 8.4.6.3 India
      • 8.4.6.3.1 Market size and forecast, by Product
      • 8.4.6.3.2 Market size and forecast, by Technique
      • 8.4.6.3.3 Market size and forecast, by Application
      • 8.4.6.3.4 Market size and forecast, by End-use
      • 8.4.6.4 South Korea
      • 8.4.6.4.1 Market size and forecast, by Product
      • 8.4.6.4.2 Market size and forecast, by Technique
      • 8.4.6.4.3 Market size and forecast, by Application
      • 8.4.6.4.4 Market size and forecast, by End-use
      • 8.4.6.5 Australia
      • 8.4.6.5.1 Market size and forecast, by Product
      • 8.4.6.5.2 Market size and forecast, by Technique
      • 8.4.6.5.3 Market size and forecast, by Application
      • 8.4.6.5.4 Market size and forecast, by End-use
      • 8.4.6.6 Rest Of Asia Pacific
      • 8.4.6.6.1 Market size and forecast, by Product
      • 8.4.6.6.2 Market size and forecast, by Technique
      • 8.4.6.6.3 Market size and forecast, by Application
      • 8.4.6.6.4 Market size and forecast, by End-use
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Product
    • 8.5.3 LAMEA Market size and forecast, by Technique
    • 8.5.4 LAMEA Market size and forecast, by Application
    • 8.5.5 LAMEA Market size and forecast, by End-use
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Product
      • 8.5.6.1.2 Market size and forecast, by Technique
      • 8.5.6.1.3 Market size and forecast, by Application
      • 8.5.6.1.4 Market size and forecast, by End-use
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Product
      • 8.5.6.2.2 Market size and forecast, by Technique
      • 8.5.6.2.3 Market size and forecast, by Application
      • 8.5.6.2.4 Market size and forecast, by End-use
      • 8.5.6.3 UAE
      • 8.5.6.3.1 Market size and forecast, by Product
      • 8.5.6.3.2 Market size and forecast, by Technique
      • 8.5.6.3.3 Market size and forecast, by Application
      • 8.5.6.3.4 Market size and forecast, by End-use
      • 8.5.6.4 South Africa
      • 8.5.6.4.1 Market size and forecast, by Product
      • 8.5.6.4.2 Market size and forecast, by Technique
      • 8.5.6.4.3 Market size and forecast, by Application
      • 8.5.6.4.4 Market size and forecast, by End-use
      • 8.5.6.5 Rest of LAMEA
      • 8.5.6.5.1 Market size and forecast, by Product
      • 8.5.6.5.2 Market size and forecast, by Technique
      • 8.5.6.5.3 Market size and forecast, by Application
      • 8.5.6.5.4 Market size and forecast, by End-use

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 erba diagnostics mannheim gmbh
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Bio-Rad Laboratories, Inc.
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Trinity Biotech Plc.
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Thermo Fisher Scientific, Inc.
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Antibodies Incorporated
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 euroimmun medizinische labordiagnostika ag
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Immuno Concepts NA Ltd.
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Inova Diagnostics, Inc.
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 ZEUS Scientific, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 2. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR REAGENTS & ASSAY KITS, BY REGION , 2021-2031,($MILLION)
  • TABLE 3. ANTINUCLEAR ANTIBODY TEST MARKET FOR REAGENTS & ASSAY KITS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 4. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SYSTEMS, BY REGION , 2021-2031,($MILLION)
  • TABLE 5. ANTINUCLEAR ANTIBODY TEST MARKET FOR SYSTEMS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 6. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SOFTWARE & SERVICES, BY REGION , 2021-2031,($MILLION)
  • TABLE 7. ANTINUCLEAR ANTIBODY TEST MARKET FOR SOFTWARE & SERVICES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 8. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 9. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR ELISA, BY REGION , 2021-2031,($MILLION)
  • TABLE 10. ANTINUCLEAR ANTIBODY TEST MARKET FOR ELISA BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 11. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR IMMUNOFLUORESCENCE ASSAY, BY REGION , 2021-2031,($MILLION)
  • TABLE 12. ANTINUCLEAR ANTIBODY TEST MARKET FOR IMMUNOFLUORESCENCE ASSAY BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 13. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR MULTIPLEX ASSAY, BY REGION , 2021-2031,($MILLION)
  • TABLE 14. ANTINUCLEAR ANTIBODY TEST MARKET FOR MULTIPLEX ASSAY BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 15. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 16. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR RHEUMATOID ARTHRITIS, BY REGION , 2021-2031,($MILLION)
  • TABLE 17. ANTINUCLEAR ANTIBODY TEST MARKET FOR RHEUMATOID ARTHRITIS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 18. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION , 2021-2031,($MILLION)
  • TABLE 19. ANTINUCLEAR ANTIBODY TEST MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 20. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SJOGREN'S SYNDROME, BY REGION , 2021-2031,($MILLION)
  • TABLE 21. ANTINUCLEAR ANTIBODY TEST MARKET FOR SJOGREN'S SYNDROME BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 22. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR SCLERODERMA, BY REGION , 2021-2031,($MILLION)
  • TABLE 23. ANTINUCLEAR ANTIBODY TEST MARKET FOR SCLERODERMA BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 24. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 25. ANTINUCLEAR ANTIBODY TEST MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 26. GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 27. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR HOSPITALS, BY REGION , 2021-2031,($MILLION)
  • TABLE 28. ANTINUCLEAR ANTIBODY TEST MARKET FOR HOSPITALS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 29. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR CLINICAL LABORATORIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 30. ANTINUCLEAR ANTIBODY TEST MARKET FOR CLINICAL LABORATORIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 31. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR PHYSICIAN OFFICE LABORATORIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 32. ANTINUCLEAR ANTIBODY TEST MARKET FOR PHYSICIAN OFFICE LABORATORIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 33. ANTINUCLEAR ANTIBODY TEST MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 34. ANTINUCLEAR ANTIBODY TEST MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 35. ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION, 2021-2031,($MILLION)
  • TABLE 36. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 37. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 38. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 39. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 40. NORTH AMERICA ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 41. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 42. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 43. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 44. U.S. ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 45. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 46. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 47. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 48. CANADA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 49. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 50. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 51. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 52. MEXICO ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 53. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 54. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 55. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 56. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 57. EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 58. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 59. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 60. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 61. GERMANY ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 62. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 63. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 64. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 65. UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 66. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 67. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 68. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 69. FRANCE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 70. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 71. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 72. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 73. SPAIN ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 74. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 75. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 76. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 77. ITALY ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 78. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 79. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 80. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 81. REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 82. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 83. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 84. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 85. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 86. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 87. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 88. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 89. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 90. CHINA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 91. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 92. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 93. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 94. JAPAN ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 95. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 96. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 97. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 98. INDIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 99. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 100. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 101. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 102. SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 103. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 104. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 105. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 106. AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 111. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 112. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 113. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 114. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 115. LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 116. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 117. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 118. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 119. BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 120. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 121. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 122. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 123. SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 124. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 125. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 126. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 127. UAE ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 128. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 129. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 130. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 131. SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 132. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2021-2031,($MILLION)
  • TABLE 133. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE, 2021-2031,($MILLION)
  • TABLE 134. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION, 2021-2031,($MILLION)
  • TABLE 135. REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE, 2021-2031,($MILLION)
  • TABLE 136.ERBA DIAGNOSTICS MANNHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 137.ERBA DIAGNOSTICS MANNHEIM GMBH: OPERATING SEGMENTS
  • TABLE 138.ERBA DIAGNOSTICS MANNHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 139.ERBA DIAGNOSTICS MANNHEIM GMBH: NET SALES,
  • TABLE 140.ERBA DIAGNOSTICS MANNHEIM GMBH: KEY STRATERGIES
  • TABLE 141.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 142.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 143.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 144.BIO-RAD LABORATORIES, INC.: NET SALES,
  • TABLE 145.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
  • TABLE 146.TRINITY BIOTECH PLC.: COMPANY SNAPSHOT
  • TABLE 147.TRINITY BIOTECH PLC.: OPERATING SEGMENTS
  • TABLE 148.TRINITY BIOTECH PLC.: PRODUCT PORTFOLIO
  • TABLE 149.TRINITY BIOTECH PLC.: NET SALES,
  • TABLE 150.TRINITY BIOTECH PLC.: KEY STRATERGIES
  • TABLE 151.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 152.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 153.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 154.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
  • TABLE 155.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 156.ANTIBODIES INCORPORATED: COMPANY SNAPSHOT
  • TABLE 157.ANTIBODIES INCORPORATED: OPERATING SEGMENTS
  • TABLE 158.ANTIBODIES INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 159.ANTIBODIES INCORPORATED: NET SALES,
  • TABLE 160.ANTIBODIES INCORPORATED: KEY STRATERGIES
  • TABLE 161.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY SNAPSHOT
  • TABLE 162.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: OPERATING SEGMENTS
  • TABLE 163.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: PRODUCT PORTFOLIO
  • TABLE 164.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: NET SALES,
  • TABLE 165.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: KEY STRATERGIES
  • TABLE 166.IMMUNO CONCEPTS NA LTD.: COMPANY SNAPSHOT
  • TABLE 167.IMMUNO CONCEPTS NA LTD.: OPERATING SEGMENTS
  • TABLE 168.IMMUNO CONCEPTS NA LTD.: PRODUCT PORTFOLIO
  • TABLE 169.IMMUNO CONCEPTS NA LTD.: NET SALES,
  • TABLE 170.IMMUNO CONCEPTS NA LTD.: KEY STRATERGIES
  • TABLE 171.INOVA DIAGNOSTICS, INC.: COMPANY SNAPSHOT
  • TABLE 172.INOVA DIAGNOSTICS, INC.: OPERATING SEGMENTS
  • TABLE 173.INOVA DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 174.INOVA DIAGNOSTICS, INC.: NET SALES,
  • TABLE 175.INOVA DIAGNOSTICS, INC.: KEY STRATERGIES
  • TABLE 176.ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 177.ZEUS SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 178.ZEUS SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 179.ZEUS SCIENTIFIC, INC.: NET SALES,
  • TABLE 180.ZEUS SCIENTIFIC, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.ANTINUCLEAR ANTIBODY TEST MARKET SEGMENTATION
  • FIGURE 2.ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031
  • FIGURE 3.ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.ANTINUCLEAR ANTIBODY TEST MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.REGULATORY GUIDELINES
  • FIGURE 13.VALUE CHAIN ANALYSIS
  • FIGURE 14.MARKET SHARE ANALYSIS
  • FIGURE 15.KEY REGULATION ANALYSIS
  • FIGURE 16.PATENT ANALYSIS BY COMPANY
  • FIGURE 17.PATENT ANALYSIS BY COUNTRY
  • FIGURE 18.ANTINUCLEAR ANTIBODY TEST MARKET,BY PRODUCT,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF REAGENTS & ASSAY KITS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SYSTEMS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SOFTWARE & SERVICES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 22.ANTINUCLEAR ANTIBODY TEST MARKET,BY TECHNIQUE,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ELISA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF IMMUNOFLUORESCENCE ASSAY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MULTIPLEX ASSAY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 26.ANTINUCLEAR ANTIBODY TEST MARKET,BY APPLICATION,2021(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF RHEUMATOID ARTHRITIS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SJOGREN'S SYNDROME ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF SCLERODERMA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 32.ANTINUCLEAR ANTIBODY TEST MARKET,BY END-USE,2021(%)
  • FIGURE 33.COMPARATIVE SHARE ANALYSIS OF HOSPITALS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 34.COMPARATIVE SHARE ANALYSIS OF CLINICAL LABORATORIES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 35.COMPARATIVE SHARE ANALYSIS OF PHYSICIAN OFFICE LABORATORIES ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 36.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031(%)
  • FIGURE 37.ANTINUCLEAR ANTIBODY TEST MARKET BY REGION,2021
  • FIGURE 38.U.S. ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 39.CANADA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 40.MEXICO ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 41.GERMANY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 42.UNITED KINGDOM ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 43.FRANCE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 44.SPAIN ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 45.ITALY ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF EUROPE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 47.CHINA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 48.JAPAN ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 49.INDIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 50.SOUTH KOREA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 51.AUSTRALIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 52.REST OF ASIA PACIFIC ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 53.BRAZIL ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 54.SAUDI ARABIA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 55.UAE ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 56.SOUTH AFRICA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 57.REST OF LAMEA ANTINUCLEAR ANTIBODY TEST MARKET,2021-2031($MILLION)
  • FIGURE 58. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 59. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 60. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 61.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 62.COMPETITIVE DASHBOARD
  • FIGURE 63.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 64.ERBA DIAGNOSTICS MANNHEIM GMBH.: NET SALES ,($MILLION)
  • FIGURE 65.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
  • FIGURE 66.TRINITY BIOTECH PLC..: NET SALES ,($MILLION)
  • FIGURE 67.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
  • FIGURE 68.ANTIBODIES INCORPORATED.: NET SALES ,($MILLION)
  • FIGURE 69.EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG.: NET SALES ,($MILLION)
  • FIGURE 70.IMMUNO CONCEPTS NA LTD..: NET SALES ,($MILLION)
  • FIGURE 71.INOVA DIAGNOSTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 72.ZEUS SCIENTIFIC, INC..: NET SALES ,($MILLION)